{
    "organizations": [],
    "uuid": "83f8ef0c5ae6029f60871d837b4779f043845a9e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-recro-pharma-receives-complete-res/brief-recro-pharma-receives-complete-response-letter-from-fda-idUSASC0A3J6",
    "ord_in_thread": 0,
    "title": "BRIEF-Recro Pharma Receives Complete Response Letter From FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 24 (Reuters) - Recro Pharma Inc:\n* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA\n* RECRO PHARMA INC - RECEIVED CRL FROM FDA REGARDING NEW DRUG APPLICATION FOR IV MELOXICAM\n* RECRO PHARMA INC - RECEIVED CRL FROM FDA OFFICE OF DRUG EVALUATION II REGARDING NEW DRUG APPLICATION (NDA) FOR IV MELOXICAM\n* RECRO PHARMA INC - CRL STATES DATA FROM AD HOC ANALYSES & SELECTIVE SECONDARY ENDPOINTS SUGGEST ANALGESIC EFFECT DOES NOT MEET EXPECTATIONS OF FDA\n* RECRO PHARMA INC - CRL RAISED CMC RELATED QUESTIONS ON EXTRACTABLE AND LEACHABLE DATA PROVIDED IN NDA\n* RECRO - CRL STATED ALTHOUGH OUTCOME OF PIVOTAL PHASE III TRIALS WERE STATISTICALLY SIGNIFICANT, FDA UNABLE TO APPROVE APPLICATION IN CURRENT FORM\n* RECRO PHARMA INC - INTEND TO REQUEST A MEETING WITH FDA AS SOON AS POSSIBLE TO DISCUSS POINTS RAISED IN CRL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-24T19:23:00.000+03:00",
    "crawled": "2018-05-25T16:32:13.019+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "recro",
        "pharma",
        "inc",
        "recro",
        "pharma",
        "receives",
        "complete",
        "response",
        "letter",
        "fda",
        "recro",
        "pharma",
        "inc",
        "received",
        "crl",
        "fda",
        "regarding",
        "new",
        "drug",
        "application",
        "iv",
        "meloxicam",
        "recro",
        "pharma",
        "inc",
        "received",
        "crl",
        "fda",
        "office",
        "drug",
        "evaluation",
        "ii",
        "regarding",
        "new",
        "drug",
        "application",
        "nda",
        "iv",
        "meloxicam",
        "recro",
        "pharma",
        "inc",
        "crl",
        "state",
        "data",
        "ad",
        "hoc",
        "analysis",
        "selective",
        "secondary",
        "endpoint",
        "suggest",
        "analgesic",
        "effect",
        "meet",
        "expectation",
        "fda",
        "recro",
        "pharma",
        "inc",
        "crl",
        "raised",
        "cmc",
        "related",
        "question",
        "extractable",
        "leachable",
        "data",
        "provided",
        "nda",
        "recro",
        "crl",
        "stated",
        "although",
        "outcome",
        "pivotal",
        "phase",
        "iii",
        "trial",
        "statistically",
        "significant",
        "fda",
        "unable",
        "approve",
        "application",
        "current",
        "form",
        "recro",
        "pharma",
        "inc",
        "intend",
        "request",
        "meeting",
        "fda",
        "soon",
        "possible",
        "discus",
        "point",
        "raised",
        "crl",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}